Trials / Completed
CompletedNCT01488331
An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer
A Patient Cohort With Locally Advanced or Metastatic Non-small Cell Lung Cancer Treated With Tarceva (Erlotinib) Monotherapy and Not Progressing After at Least 9 Months
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 217 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective, multi-center, observational study will assess the progression-free survival and safety of patients with locally advanced or metastatic non-small cell lung cancer treated with Tarceva (erlotinib) and not disease progressing after at least 9 months. Data will be collected for 24 months.
Conditions
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2013-11-01
- Completion
- 2013-11-01
- First posted
- 2011-12-08
- Last updated
- 2016-11-02
Locations
92 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01488331. Inclusion in this directory is not an endorsement.